AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tryptamine Therapeutics Ltd

0.034

0.000

Volume:- -

Turnover:- -

Market Cap:54.72M

PE:-8.72

High:0.034

Open:0.034

Low:0.034

Close:0.034

52wk High:0.050

52wk Low:0.027

Shares:1.61B

Float Shares:878.05M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.004

EPS(LYR):-0.004

ROE:-92.06%

ROA:-45.59%

PB:9.18

PE(LYR):-8.79

Loading ...

Overview Company News Filings

Tryptamine Therapeutics To Raise A$6.1 Million At A$0.034 Per Share

Tryptamine Therapeutics Ltd-September 2025 Quarterly Activities Report Correction

THOMSON REUTERS

BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement

BRIEF-Tryptamine Therapeutics To Raise A$6.1 Million At A$0.034 Per Share

Tryptamine Therapeutics Ltd - to Raise a$6.1 Mln at a$0.034 per Share

THOMSON REUTERS

BRIEF-Tryptamine Therapeutics Requests Trading Halt For Capital Raising

Tryptamine Therapeutics Ltd-Trading Halt

THOMSON REUTERS

Tryptamine Therapeutics Ltd-Quarterly Activities Report and Appendix 4C

THOMSON REUTERS

Tryptamine Therapeutics Enters Exclusive Agreement for Development of Proprietary Electroencephalogram-Based Biomarker Platform

MT Newswires Live

Tryptamine Therapeutics Enters Facility Agreement to Fund R&D Expenditure; Shares Rise 3%

MT Newswires Live

BRIEF-Tryptamine Therapeutics Secures A$2.6M In Non-Dilutive Capital To Fast Track Trp-8803 Clinical Development

Tryptamine Therapeutics Ltd - a$2.6M in Non-Dilutive Capital Secured to Fast Track Trp-8803 Clinical Development

THOMSON REUTERS

Tryptamine Therapeutics to Start Supplying Drug Product for Binge Eating Trial at University; Shares Rise 3%

MT Newswires Live

Tryptamine Therapeutics Launches Clinical Trial for Binge Eating Disorder Treatment Candidate; Shares Up 3%

MT Newswires Live

Key appointments strengthen TRP-8803 clinical development-TYP.AX

Investor Presentation-TYP.AX

Tryptamine Therapeutics Receives Ethics Approval for Eating Disorder Trial

MT Newswires Live

ASX ALERT-Binge Eating Disorder Trial receives Human Ethics approval-TYP.AX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TYP.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TYP.AU\",,,,,undefined,":{"symbol":"TYP.AU","market":"AU","secType":"STK","nameCN":"Tryptamine Therapeutics Ltd","latestPrice":0.034,"timestamp":1770613200000,"preClose":0.034,"halted":8,"volume":0,"delay":0,"changeRate":0,"nameEN":"Tryptamine Therapeutics Ltd","floatShares":878046607,"shares":1609510143,"eps":-0.0039,"marketStatus":"Not Yet Opened","change":0,"latestTime":"02-09 16:00:00 AEDT","open":0.034,"high":0.034,"low":0.034,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0039,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.034,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TYP.AU\",,,,,undefined,":{"symbol":"TYP.AU","floatShares":878046607,"roa":"-45.59%","roe":"-92.06%","lyrEps":-0.003868,"shares":1609510143,"dividePrice":0,"high":0.034,"amplitude":0,"preClose":0.034,"low":0.034,"week52Low":0.027,"pbRate":"9.18","psRate":"34.60","week52High":0.05,"institutionHeld":0,"latestPrice":0.034,"eps":-0.0039,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.0039,"open":0.034},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TYP.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-11-21","symbol":"TYP.AU","oldSymbol":"TYP","defaultRemindTime":1763679600000,"newSymbol":"ENP.AU","exchange":"ASX","type":"symbolChange","dateTimestamp":1763643600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TYP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TYP.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584143925","title":"Tryptamine Therapeutics To Raise A$6.1 Million At A$0.034 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2584143925","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584143925?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:33","pubTimestamp":1763570020,"startTime":"0","endTime":"0","summary":"Nov 5 (Reuters) - Tryptamine Therapeutics Ltd ::*TO RAISE A$6.1 MILLION AT A$0.034 PER SHARE*Further company coverage: TYP.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202501:44:42 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD8jbPxf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","TYP.AU"],"gpt_icon":0},{"id":"2581216050","title":"Tryptamine Therapeutics Ltd-September 2025 Quarterly Activities Report Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=2581216050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581216050?lang=en_us&edition=fundamental","pubTime":"2025-11-07 11:32","pubTimestamp":1762486335,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUE3DKJGK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2581718333","title":"BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2581718333","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581718333?lang=en_us&edition=fundamental","pubTime":"2025-11-05 10:19","pubTimestamp":1762309163,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Tryptamine Therapeutic falls on discounted placement** Tryptamine Therapeutic TYP.AX falls 2.6% to A$0.037; on track for steepest intraday pct decline since October 27** Biotechnology","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL6N3WH03T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2581797774","title":"BRIEF-Tryptamine Therapeutics To Raise A$6.1 Million At A$0.034 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2581797774","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581797774?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:44","pubTimestamp":1762307082,"startTime":"0","endTime":"0","summary":"BRIEF-Tryptamine Therapeutics To Raise A$6.1 Million At A$0.034 Per ShareNov 5 (Reuters) - Tryptamine Therapeutics Ltd TYP.AX:TO RAISE A$6.1 MILLION AT A$0.034 PER SHAREFurther company coverage: TYP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WG1TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","TYP.AU"],"gpt_icon":0},{"id":"2581793334","title":"Tryptamine Therapeutics Ltd -  to Raise a$6.1 Mln at a$0.034 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2581793334","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581793334?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:38","pubTimestamp":1762295921,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG1TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","TYP.AU"],"gpt_icon":0},{"id":"2580214231","title":"BRIEF-Tryptamine Therapeutics Requests Trading Halt For Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2580214231","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580214231?lang=en_us&edition=fundamental","pubTime":"2025-11-03 06:23","pubTimestamp":1762122189,"startTime":"0","endTime":"0","summary":"BRIEF-Tryptamine Therapeutics Requests Trading Halt For Capital RaisingNov 3 (Reuters) - Tryptamine Therapeutics Ltd TYP.AX:TRADING HALTTRADING HALT REQUESTED FOR CAPITAL RAISINGFurther company coverage: TYP.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251102:nTUE4VS0X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2580231242","title":"Tryptamine Therapeutics Ltd-Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2580231242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580231242?lang=en_us&edition=fundamental","pubTime":"2025-11-03 06:22","pubTimestamp":1762122132,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251102:nTUE4VS0X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","TYP.AU"],"gpt_icon":0},{"id":"2579432282","title":"Tryptamine Therapeutics Ltd-Quarterly Activities Report and Appendix 4C","url":"https://stock-news.laohu8.com/highlight/detail?id=2579432282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579432282?lang=en_us&edition=fundamental","pubTime":"2025-10-31 15:19","pubTimestamp":1761895182,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUE2FLFCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","TYP.AU"],"gpt_icon":0},{"id":"2561592459","title":"Tryptamine Therapeutics Enters Exclusive Agreement for Development of Proprietary Electroencephalogram-Based Biomarker Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2561592459","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561592459?lang=en_us&edition=fundamental","pubTime":"2025-08-21 14:43","pubTimestamp":1755758586,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics (ASX:TYP) entered into an exclusive biomarker development agreement with Robin Carhart-Harris, the Chair of the firm's scientific advisory board and Pedro Mediano, a professor ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TYP.AU","BK7096","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2558136926","title":"Tryptamine Therapeutics Enters Facility Agreement to Fund R&D Expenditure; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558136926","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558136926?lang=en_us&edition=fundamental","pubTime":"2025-08-12 12:45","pubTimestamp":1754973928,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics  entered into a loan facility agreement with funding firm, Rockford Equity, for the company's AU$2.6 million research and development activities, according to a Tuesday filing with the Australian bourse.The company can borrow in AU$500,000 amounts from the facility, with interest of 16% per year on the outstanding balance, the filing said.Shares of the company rose past 3% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","TYP.AU","BK4539","BK7096"],"gpt_icon":0},{"id":"2558694347","title":"BRIEF-Tryptamine Therapeutics Secures A$2.6M In Non-Dilutive Capital To Fast Track Trp-8803 Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2558694347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558694347?lang=en_us&edition=fundamental","pubTime":"2025-08-12 09:31","pubTimestamp":1754962264,"startTime":"0","endTime":"0","summary":"BRIEF-Tryptamine Therapeutics Secures A$2.6M In Non-Dilutive Capital To Fast Track Trp-8803 Clinical DevelopmentAug 12  - Tryptamine Therapeutics Ltd TYP.AX:A$2.6M IN NON-DILUTIVE CAPITAL SECURED TO FAST TRACK TRP-8803 CLINICAL DEVELOPMENTFurther company coverage: TYP.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nFWN3U31DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","TYP.AU"],"gpt_icon":0},{"id":"2558141695","title":"Tryptamine Therapeutics Ltd - a$2.6M in Non-Dilutive Capital Secured to Fast Track Trp-8803 Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2558141695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558141695?lang=en_us&edition=fundamental","pubTime":"2025-08-12 06:29","pubTimestamp":1754951398,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nFWN3U31DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2557580820","title":"Tryptamine Therapeutics to Start Supplying Drug Product for Binge Eating Trial at University; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557580820","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557580820?lang=en_us&edition=fundamental","pubTime":"2025-08-07 11:21","pubTimestamp":1754536910,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics  will start supplying its psilocin-based drug, TRP-8803, to Swinburne University as part of a clinical trial targeting binge eating disorder, following the university's receipt of a permit to obtain controlled substances for research, according to a Thursday filing with the Australian bourse.Several trial candidates have now completed the preliminary screening process and are scheduled for interviews next week, to be followed by initial enrollments, the filing said.Shares of the company rose past 3% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TYP.AU","BK4539","BK7096","LENZ","BK4139"],"gpt_icon":0},{"id":"2553763442","title":"Tryptamine Therapeutics Launches Clinical Trial for Binge Eating Disorder Treatment Candidate; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553763442","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553763442?lang=en_us&edition=fundamental","pubTime":"2025-07-21 09:46","pubTimestamp":1753062390,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics  launched patient recruitment for its clinical trial testing TRP-8803 combined with psychotherapy to potentially treat binge eating disorder , according to a Monday Australian bourse filing.The trial will enroll 12 BED patients in two groups of six, with each patient receiving two doses of TRP-8803 spaced 14 days apart following preparatory psychotherapy, the filing said. The first group will receive a mid-range dose, and the second group a high-range dose.Recruitment started after completing key activities such as obtaining governance approval, submitting permits, finalizing patient cohort protocols, hiring staff, preparing patient-focused materials, and scheduling TRP-8803 manufacturing for the study, the filing added.First dosing is scheduled for this quarter, with results expected by the fourth quarter, per the filing.Tryptamine Therapeutics' shares jumped 3% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TYP.AU","BK7096","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2551190840","title":"Key appointments strengthen TRP-8803 clinical development-TYP.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551190840","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551190840?lang=en_us&edition=fundamental","pubTime":"2025-07-16 06:53","pubTimestamp":1752620000,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250715:nASX3QHPR0","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nASX8rFtsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2546224445","title":"Investor Presentation-TYP.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546224445","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546224445?lang=en_us&edition=fundamental","pubTime":"2025-06-26 07:09","pubTimestamp":1750892966,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nASX92WLVZ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nASX5gNZ1M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TYP.AU","BK7096"],"gpt_icon":0},{"id":"2545452486","title":"Tryptamine Therapeutics Receives Ethics Approval for Eating Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2545452486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545452486?lang=en_us&edition=fundamental","pubTime":"2025-06-23 09:26","pubTimestamp":1750642000,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics  received approval from the Swinburne University Human Research Ethics Committee to initiate an open-label study to assess the safety and efficacy of TRP-8803 in combination with psychotherapy in adult patients with binge eating disorder, according to a Monday filing with the Australian bourse.The main goal of the trial is to determine the safety and effectiveness of two TRP-8803 doses over a 12-week follow-up period after the second dose.TRP-8803 is a psilocin-based intravenous-infusion formulation with potential neuroplastic benefits, the filing said.The trial will administer two doses of TRP-8803 to 12 participants in two patient cohorts, 14 days apart.Secondary and exploratory objectives include assessing TRP-8803's ability to induce a psychedelic state and its impact on binge-eating frequency and other weight-related measures at both four and 12 weeks post-second dosing, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","TYP.AU","LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2545036459","title":"ASX ALERT-Binge Eating Disorder Trial receives Human Ethics approval-TYP.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545036459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545036459?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:33","pubTimestamp":1750635207,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250622:nASXbjS3Z7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nASXMtmkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","TYP.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}